Turgeon Joseph W., CEO & President, subtracted 18,240 shares of Spectrum Pharmaceuticals, Inc. (SPPI) from its portfolio at the rate of $7.95 per share valuing $145,070 on Jun 06. The insider left behind 430,977 shares of the company to its portfolio. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Spectrum Pharmaceuticals, Inc. (SPPI) was $7.45. Currently, the 1st Resistance Point for this stock is $7.63, with a 2nd Resistance Point sitting at $7.80. Meanwhile, this company’s stock has a 1st Support Level at $7.34 and a 2nd Support Level at $7.22. Spectrum Pharmaceuticals, Inc. (SPPI) stock has lost -$0.53, or -6.64%, in the past five days. In the last full month, these shares have lost -$1.33, or -15.15%. In the past three months, this stock’s price has fallen by -$2.83, or -27.53%. This year-to-date, Spectrum Pharmaceuticals, Inc. (SPPI) shares have lost -$1.30, or -14.86%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Spectrum Pharmaceuticals, Inc. (SPPI) stock, 80% of short-term indicators suggest that these shares are a “ Sell .” Meanwhile, 75% of medium-term indicators point to this stock being a “ Sell .” Looking further ahead, 100% of long-term indicators suggest that this stock is a “ Sell .”
With 111,963 K shares outstanding, this company currently has a market capitalization of $834,124K. Spectrum Pharmaceuticals, Inc. (SPPI) generates $109,330 K in annual sales, amounting to annual net income of -$120,010 K. This stock has generated a 1-Year Total Return of -62.75%, a 3-Year Total Return of 10.21%, and a 5-year Total Return of -8.59%. This stock’s 5-Year Dividend Growth is 0.00%, with its most recent dividend valued at $0.150 per share on 12/18/12. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in Mar-19, Spectrum Pharmaceuticals, Inc. (SPPI) reported earnings of -$0.27 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$0.23 per share, representing a -0.04 difference and -17.39% surprise. In the previous quarter ending in Dec-18, the reported earnings of -$0.30 represented a -0.09 difference from the consensus estimate calling for -$0.21 per share, which was a -40.65% surprise.
For the current fiscal quarter, which is set to end in 06/2019, the average earnings estimate is -$0.36 per share. This estimate came from a total of 1 Wall Street Analysts. Of those market experts, the high estimate was -$0.36 and the low estimate was -$0.36. In the year-ago quarter, Spectrum Pharmaceuticals, Inc. (SPPI) generated per-share earnings of -$0.24. If the analysts are correct about the current quarter’s earnings, the growth will be -50.00% .
Turning our focus now to insider trading activity, there have been 6 purchases (108,500 shares in total) and 18 sale (189,647 shares in total) in the last 3 months. In the last 6 months, there have been 18 insider buys amounting to 574,260 shares and 30 insider sales amounting to 309,238 shares. In the past full year, 30 insider purchases were made (involving 713,760 shares) and 35 insider sell-offs equivalent to 334,410 shares.
Moving onto liquidity, Spectrum Pharmaceuticals, Inc. (SPPI) has a Current Ratio of 2.90, a Quick Ratio of 2.86 and a Cash Ratio of 2.36.